Prostate Cancer's Hidden Flaw Triggers Self-Destruction
Researchers have identified that blocking the enzymes PDIA1 and PDIA5 can destabilize the androgen receptor in prostate cancer cells, leading to cell death and tumor shrinkage. Combining inhibitors of these enzymes with existing treatments like enzalutamide enhances effectiveness, offering a promising new approach to overcoming treatment resistance in prostate cancer. The findings suggest that targeting these enzymes could weaken cancer cells by disrupting both their growth signals and energy production, paving the way for more effective therapies.
